Basic | |
---|---|
Market Cap | $5.36M |
Price | $13.44 |
52 Week Range | 0.93-2.39 |
Beta | 1.68 |
Margins | |
Gross Profit Margin | 0.00% |
Operating Profit Margin | 0.00% |
Net Profit Margin | 0.00% |
Valuation (TTM) | |
P/E Ratio | -22.09 |
Price to Sales Ratio | 0.00 |
Price to Book Ratio | 12.88 |
PEG Ratio | -0.69 |
Biotechnology
Healthcare
2021-03-22T00:00:00.000Z
Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was incorporated in 2019 and is headquartered in Vancouver, Canada.
647 407 2515
1500 – 1055 West Georgia Street, Vancouver, BC, V6E 4N7, CA
0001827401